secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001641172-25-000923
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M
--------------------------------------------------------------------------------

- Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).
- FY product revenue $9.2M (flat YoY); tests ~24,305 (+1.3%); AUP $378 (-1.0%); gross margin 59.7% (+2.2 ppts).
- Operating expenses Q4 $4.9M (-8% YoY); FY $21.8M (-10% YoY).
- Cash ~$3.7M as of Mar 27, 2025; pending $1.5M ARPA-H milestone; raised $5.75M via convertible notes and ATM.
- New CEO Mike Buhle appointed; ARPA-H $10M award milestone; Ellen Beausang added to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000164117225000923/0001641172-25-000923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000164117225000923/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer